Nanovista

Nanovista is a clinical-stage biotechnology company specializing in the development of multimodal contrast agents designed to enhance the precision of image-guided oncology procedures. The company's core technology is a liposomal nanoparticle platform that enables simultaneous visualization of tumors across CT, MRI, and optical imaging modalities. Their lead candidate, Spark, provides real-time surgical guidance to help clinicians identify tumor margins and map lymph nodes with high accuracy. By integrating diagnostic-quality imaging into the operating room, Nanovista seeks to improve surgical outcomes and reduce the incidence of positive margins. The company is a spin-off from the University Health Network and the University of Toronto.